Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a Chinese pharmaceutical company, has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its innovative drug candidate HSK39775, intended for the treatment of advanced solid tumors.
Preclinical study results have demonstrated HSK39775’s potential efficacy across multiple tumor cell lines and strong anti-tumor activity in models with homologous recombination repair defects. This suggests its potential use in treating cancers associated with homologous recombination repair deletions, particularly those related to BRCA mutations, such as breast, ovarian, and prostate cancers. HSK39775 has also shown good selectivity and safety in preclinical studies, positioning it as a highly promising small molecule drug candidate for further development. Currently, most drugs targeting the same mechanism worldwide are in the early stages of development, with the most advanced being in Phase I clinical trials.
This clinical trial approval marks a significant step for Haisco Pharmaceutical Group as it moves towards advancing its pipeline and contributing to the global effort in developing new cancer treatments.- Flcube.com
